目的: 探讨甲状腺相关性眼病(thyroid-associated ophthalmopathy, TAO) 患者外周血CD19+CD27+IgD+B细胞比例变化与病情活动度的关系。方法: 采用流式细胞术检测TAO患者和健康对照组CD19+CD27+IgD+B细胞比例,分析TAO患者CD19+CD27+IgD+B细胞比例与健康对照组的差异,并分析CD19+CD27+IgD+B细胞比例与TAO疾病活动度之间的相关性。结果: TAO患者CD19+CD27+IgD+B细胞比例明显低于健康对照 (P＜0.05) ;活动性TAO患者CD19+CD27+IgD+B细胞比例细胞显著低于非活动性TAO患者; CD19+CD27+IgD+B细胞比例与TAO患者CAS评分呈显著负相关 (r=-0.7128,P＜0.001) 。结论: TAO患者CD19+CD27+IgD+B细胞比例降低,与疾病活动度呈负相关。
Objective: To investigate the relationship between the proportion of CD19+CD27+IgD+B cells in peripheral blood and disease activity in patients with thyroid-associated ophthalmopathy (TAO). Methods: Flow cytometry was used to detect the proportion of CD19+CD27+IgD+B cells in TAO patients and healthy control groups. The difference in the proportion of CD19+CD27+IgD+B cells between TAO patients and healthy control groups was analyzed. The correlation between the proportion of CD19+CD27+IgD+B cells and activity was also analyzed. Results: The proportion of CD19+CD27+IgD+B cells in TAO patients was significantly lower than that in healthy controls (P＜0.05). The proportion of CD19+CD27+IgD+B cells in active TAO patients was significantly lower than in inactive TAO patients. The proportion of CD19+CD27+IgD+B cells was significantly negatively correlated with the CAS score of TAO patients (r=-0.7128, P＜0.001). Conclusion: The proportion of CD19+CD27+IgD+B cells in TAO patients is decreased, which is negatively correlated with disease activity.
[1] Subekti I, Soewondo P, Soebardi S, et al. Practical guidelines management of Graves ophthalmopathy[J]. Acta Med Indones, 2019,51(4):364-371.
[2] Antonelli A, Fallahi P, Elia G, et al. Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy[J]. Best Pract Res Clin Endocrinol Metab, 2020,34(1):101388.
[3] SteinJD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease[J]. JAMA Ophthalmol, 2015,133(3):290-296.
[4] Wang Y, Tooley AA, Mehta VJ, et al. Thyroid orbitopathy[J]. Int Ophthalmol Clin, 2018,58(2):137-179.
[5] Phan TT, Sun L, Bay BH, et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring[J]. J Trauma, 2003,54(6):1212-1224.
[6] Park MJ, Kwok SK, Lee SH, et al. Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus[J]. Cell Transplant, 2015,24(11):2367-2377.
[7] Zha BB, Wang LM, Liu XM, et al. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease[J]. PLoS One, 2012,7(11):e49835.
[8] Chen G, Ding YG, Li Q, et al. Defective regulatory B cells are associated with thyroid-associated ophthalmopathy[J]. J Clin Endocrinol Metab, 2019,104(9):4067-4077.
[9] Hu FL, Zhang W, Shi LJ, et al. Impaired CD27+IgD+ B cells with altered gene signature in rheumatoid arthritis[J]. Front Immunol, 2018,9:626.
[10] Zhang W, Wang YF, Hu FL, et al. Dysfunction of CD27+IgD+ B cells correlates with aggravated systemic lupus erythematosus[J]. Clin Rheumatol, 2022,41(5):1551-1559.
[11] Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future[J]. Autoimmunity, 2010,43(1):84-97.
[12] Shovman O, Gilburd B, Shoenfeld Y. The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment?[J]. J Rheumatol, 2006,33(3):445-447.
[13] Hanaoka H, Okazaki Y, Hashiguchi A, et al. Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2015,33(6):863-870.
[14] Li XJ, Zhong H, Bao WL, et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia[J]. Blood, 2012,120(16):3318-3325.
[15] Lin W, Jin LX, Chen H, et al. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjgren’s syndrome: the similarities and differences[J]. Arthritis Res Ther, 2014,16(3):R118.
[16] Aybar LT, Mcgregor JG, Hogan SL, et al. Reduced CD5+CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies[J]. Clin Exp Immunol, 2015,180(2):178-188.
[17] Kim J, Lee HJ, YooI S, et al. Regulatory B cells are inversely associated with disease activity in rheumatoid arthritis[J]. Yonsei Med J, 2014,55(5):1354-1358.
[18] Zhu HQ, Xu RC, Chen YY, et al. Impaired function of CD19+ CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus[J]. Br J Dermatol, 2015,172(1):101-110.
[19] Kristensen B, Hegedus L, Lundy SK, et al. Characterization of regulatory B cells in Graves' disease and hashimoto’s thyroiditis[J]. PLoS One, 2015,10(5):e0127949.
